DB16996ExperimentalGene Therapies
TSHA-118 is a self-complementary AAV9 gene replacement therapy designed to express a human codon-optimized CLN1 transgene for the treatment of CLN1 disease.
- Also known as
- TSHA 118 ยท TSHA118
- Code names
- ABO-202
Which companies are running trials of TSHA-118, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account